Registration Header

NGM Biopharmaceuticals, Inc. R&D Day 2020

Start Date:12/9/2020

Start Time:12:00 PM EST

Duration:210 minutes


Join the NGM (Nasdaq: NGM) management team and industry KOLs for a virtual R&D Day highlighting how NGM’s 100+ researcher-led discovery engine is harnessing powerful, untapped biology to create transformative therapeutics.

If you're already registered for the NGM Biopharmaceuticals, Inc. R&D Day 2020 webcast, click below:



David Woodhouse, Ph.D.

Chief Executive Officer


Dr. Woodhouse became Chief Executive Officer and a member of NGM’s board of directors in September 2018. He previously served as NGM’s Chief Financial Officer, joining the company in March 2015. From 2002 to 2015, he was an investment banker at Goldman Sachs & Co. LLC, most recently as a Managing Director in the healthcare investment banking group and co-head of biotechnology investment banking. Earlier in his career, Dr. Woodhouse worked at Dynavax Technologies and also as a research assistant at Amgen, Inc. Dr. Woodhouse received a B.A. in pharmacology from the University of California, Santa Barbara, an M.B.A. from the Tuck School of Business at Dartmouth and a Ph.D. in molecular pharmacology from Stanford University School of Medicine.

Jin-Long Chen, Ph.D.

Founder and Chief Scientific Officer


Dr. Chen is NGM’s Founder and has served as a member of our board of directors and as Chief Scientific Officer since January 2008. He was also NGM’s President until November 2014. Previously, Dr. Chen held various positions at Amgen, most recently as its Vice President, Metabolic Disorders, with responsibility for leading the company’s global research efforts in small molecule and biologic drug discovery for the treatment of human diseases affecting metabolism, bone, mineral balance and muscle. Prior to joining Amgen, he served as Vice President of Biology at Tularik where he guided drug discovery research in oncology, inflammation and metabolic disease. Dr. Chen’s pioneering work on a broad array of targets at both Amgen and Tularik not only opened up opportunities to study new aspects of biology and physiology across disease areas, but also led to contributions of multiple drug candidates to the development pipelines of these organizations, including RepathaTM (evolocumab), a novel anti-PCSK9 antibody that lowers low-density lipoprotein cholesterol.

Alex DePaoli, M.D.

SVP, Chief Translational Officer


Prior to his current role as NGM’s Chief Translational Officer, Dr. DePaoli served as NGM’s founding Chief Medical Officer (CMO). Before joining NGM in 2010, Dr. DePaoli was CMO at IntreKin Therapeutics. In this role he oversaw global development of INT131, a PPAR-gamma modulator, through a successful End of Phase 2 meeting with the FDA. He brings to NGM more than 20 years of experience as a clinician and translational researcher in diabetes, obesity and metabolic disease. Dr. DePaoli trained in Clinical and Molecular Endocrinology at the University of Chicago and in the Howard Hughes laboratory of Dr. Graham Bell. His clinical and translational research interests in diabetes and obesity were focused during his work at the Sansum Diabetes Research Institute which led him to join Amgen in 1998 to champion the development of their cardiometabolic disease portfolio. His work at Amgen was pivotal in enabling multiple clinical applications of the adipocytokine leptin (Myalept). At Amgen, he also led a broad array of cardiometabolic, muscle and bone programs with a focus on translating novel pathways into the clinic. These pathways included: RANK Ligand (now Prolia and Xgeva), PCSK9 (Evolocumab), 11 Beta HSD-1, Myostatin, IL-1 receptor, Calcium Sensing Receptor (Sensipar), PPAR-gamma modulation, DPP-4 and MCH-R1. Dr. DePaoli also maintains a clinical endocrinology practice at the William Sansum Diabetes Center.

Daniel Von Hoff, M.D., F.A.C.P.

Distinguished Professor

The Translational Genomics Research Institute

Daniel D. Von Hoff, M.D., F.A.C.P. FASCO, FAACR is a Distinguished Professor at the Translational Genomics Research Institute (TGen) in Phoenix, Arizona. He holds the Virginia G. Piper Distinguished Chair for Innovative Cancer Research at HonorHealth Clinical Research Institute and the Margaret Givan Larkin Endowed Chair in Developmental Cancer Therapeutics at Hoag Hospital and Medical Director of Research at McKesson Specialty Health and the Chief Scientific Officer for US Oncology Research specializing in phase I clinical trials. He is also Professor of Medicine at the University of Arizona and at the Mayo Clinic, Scottsdale, AZ and Senior Consultant of Clinical Investigation at the City of Hope. Dr. Von Hoff’s major interest is in the development of new anticancer agents, both in the clinic and in the laboratory. He and his colleagues were involved in the beginning of the development of many FDAapproved agents we now use routinely, including: mitoxantrone, fludarabine, paclitaxel, docetaxel, gemcitabine, irinotecan, nelarabine, capecitabine, lapatinib, vismodegib, nab-paclitaxel, nal-IRI, pexidartinib and others. His clinical trial work has led to the approval of 3 of the 4 drugs approved by the FDA for treatment of patients with advanced pancreatic cancer. At present, he and his colleagues are concentrating on the development of therapies for patients with advanced pancreatic cancer. Dr. Von Hoff has published more than 741 papers, 143 book chapters and over 1186 abstracts. Dr. Von Hoff received the 2010 David A. Karnofsky Memorial Award from the American Society of Clinical Oncology for his outstanding contributions to cancer research leading to significant improvement in patient care and most recently the AACR Distinguished Public Service Award in recognition of his extraordinary clinical research career and leadership in establishing the AACR/ASCO Methods in Clinical Cancer Research Workshop to educate and train young clinical investigators. Dr. Von Hoff was appointed to President Bush’s National Cancer Advisory Board in 2004-2010. Dr. Von Hoff is the past President of the American Association for Cancer Research (the world’s largest cancer research organization), a Fellow of the American College of Physicians, and a member and past board member of the American Society of Clinical Oncology. He is a founder of ILEX™ Oncology, Inc. (acquired by Genzyme after Ilex had 2 agents, alemtuzumab and clofarabine approved by the FDA for patients with leukemia). Dr. Von Hoff is founder and the Editor Emeritus of Investigational New Drugs – The Journal of New Anticancer Agents; and, past Editor-in-Chief of Molecular Cancer Therapeutics. He is a co-founder of the AACR/ASCO Methods in Clinical Trial Cancer Research Workshop, which has graduated more than 2100 clinical trial physicians. He is also proud to have been a mentor and teacher for multiple medical students, medical oncology fellows, graduate students, and post-doctoral fellows.

Robert Schreiber, Ph.D.

Distinguished Professor

Pathology & Immunology, Washington University School of Medicine

Dr. Schreiber is an immunologist and currently is the Alumni Endowed Professor of Pathology and Immunology at Washington University School of Medicine. Schreiber has led a major revision in our understanding of how the immune system interacts with cancer. His work on the cancer immunoediting hypothesis has helped reveal that the immune system is not only capable of destroying cancers, but can also drive them into a dormant state that, in some cases, results in an improved state of malignancy. Schreiber obtained his B.A. and PhD in biochemistry from the State University of New York at Buffalo. His postdoctoral training was with Han Mueller-Eberhart at the Scripps Clinic studying the complement system. He joined the Scripps faculty in 1976 and rose to associate member with tenure at Scripps before joining Washington University in St. Louis as Professor of Pathology. He was given the Alumni Endowed Professorship in 1990 and became an Affiliate of the Ludwig Institute for Cancer Research in 2001.

Dan Kaplan, Ph.D.

Director, Biology


Dr. Kaplan joined NGM in 2008. He co-leads NGM’s Immune-Oncology research team and serves as leader of the NGM707 (anti-ILT2/ILT4) development team. He has directed drug discovery efforts across numerous therapeutic areas, including metabolic diseases and oncology. For the past five years, his team has worked to understand the suppressive mechanisms at play in the tumor microenvironment, and how these mechanisms restrict anti-tumor immune responses in many cancers. They have elucidated a “myeloid checkpoint” that mediates immune suppression in tumors, and they have identified therapeutic targets for relieving this checkpoint. Dr. Kaplan obtained his Ph.D. from Duke University, where he was a Howard Hughes Medical Institute predoctoral scholar, and completed postdoctoral training at Stanford University, where he was an American Cancer Society fellow.

James Sissons, Ph.D.

Director, Biology

NGM Biopharmaceuticals

Dr. James Sissons is an Immunologist with extensive experience in cancer research and development. James serves as Director of the Immuno-Oncology group and the co-lead of NGM438 development team where he engineers novel drugs to activate the immune system to recognize and eliminate cancer cells. Prior to NGM, James lead research and development programs in T cell receptor engineered T-cell therapeutics for Juno Therapeutics in Seattle, advancing medicines that are in clinical development. James obtained his Ph.D. in Biology from Birkbeck College, University of London, and completed postdoctoral training in infectious diseases and genetics at Harvard University. He has extensively published in peer-reviewed journals including Nature Medicine, Cell, Journal of Experimental Medicine, and Proceedings of the National Academy of Sciences.

Erin Henry

Head of Ophthalmology


Specialties: Ophthalmology, Neuroscience • 10+ years of pharmaceutical experience in Medical Affairs, Product Development, and Marketing • Deep therapeutic area expertise in age-related macular degeneration and retinal vascular disease • Well established Ophthalmology/Retina healthcare provider network • Product launch planning and execution experience • Global company-sponsored trial (Phase Ia-IV) and investigator initiated trial (IST/IIS) experience • Strong basic research background in biochemistry and neuroscience

Charles Wykoff, M.D., Ph.D.

Director of Research

Weill Cornell Medical College, Houston Methodist Hospital

Charles C. Wykoff MD PhD is Director of Research, Retina Consultants of Houston; Chairman of Research and Clinical Trials Subcommittee, Retina Consultants of America; Deputy Chair for Ophthalmology, Blanton Eye Institute and Associate Clinical Professor of Ophthalmology, Weill Cornell Medical College, Houston Methodist Hospital, Houston Texas. He received his baccalaureate from MIT, PhD from Oxford University while on a Marshall Scholarship, and MD from Harvard Medical School. He completed ophthalmology residency and vitreoretinal fellowship at Bascom Palmer Eye Institute where he served as Chief Resident/Co-Director of Ocular Trauma and received a Heed Fellowship and the Ronald G. Michels Award. Dr. Wykoff is passionate about translational research and clinical trial design, and has published over 140 peer reviewed manuscripts. His research interests pertain to angiogenesis and retinal vascular diseases as well as vitreoretinal surgical topics. He has been awarded the AAO Secretariat and Achievement Awards as well as the ASRS Honor and Senior Honor Awards. He is an elected member of The Retina Society and The Macula Society, was a founding member of the Ophthalmology Retina Editorial Board, and serves as the President-elect for the Vit-Buckle Society. Dr Wykoff is actively involved in entrepreneurial activities and serves on multiple scientific advisory boards and global clinical-trial steering committees for companies spanning the innovative process from early to late stage development. His guiding philosophy is to build and strengthen innovative, ethical teams focused on developing new approaches to improving outcomes for blinding diseases.

Hsiao D. Lieu, M.D.

SVP, Chief Medical Officer


Dr. Lieu joined NGM in March 2019 and brings more than 15 years of experience leading clinical development programs and executing integrated medical and commercial strategies across a spectrum of therapeutic areas. In both large pharmaceutical and biotechnology companies, Dr. Lieu has led teams responsible for preclinical through phase 3 development, as well as medical affairs. Prior to NGM, Dr. Lieu worked at Genentech as Vice President of Early Clinical Development for all non-oncology molecules. He also worked at Eli Lilly, where he held various leadership roles, including Global Brand Development Leader for Taltz®, Managing Director and Vice President at Lilly’s internal early clinical development and research division Chorus , Head of Global Clinical Pharmacology for diabetes, and Senior Medical Director of U.S. Medical Affairs for a number of cardiovascular and autoimmune products. Prior to joining Lilly, Dr. Lieu was a co-founder and CEO of RetinoRx, LLC and Chief Medical Officer/Executive Vice President at Niles Therapeutics, Inc. Earlier in his career, he held clinical development leadership roles with Portola Pharmaceuticals, Inc. and CV Therapeutics, Inc. (acquired by Gilead).

Corinne Foo-Atkins, M.D., MBA, MSc

Vice President, Product Strategy


Dr Foo-Atkins joined NGM in 2017 to build a commercial planning function and steward the aldafermin program. Her experience spans project team leadership on early-stage molecules at Genentech; strategic marketing, market access, pricing and policy roles at Novartis Pharma’s global headquarters; and strategy consulting in the Pharmaceuticals and Medical Products Practice at McKinsey and Company. Dr Foo-Atkins was a practicing physician trained at the National University of Singapore. She also holds an MBA from the Kellogg School of Business and a Master in Health Economics, Policy and Management from the London School of Economics.

Manal Abdelmalek, M.D.

Professor of Medicine, Duke University School of Medicine

Director, NAFLD Clinical Research Program, Duke University

Manal F. Abdelmalek, MD, MPH is tenured Professor of Medicine in the Division of Gastroenterology and Hepatology and Director of the Nonalcoholic Fatty Liver Disease (NAFLD) Clinical Research Program at Duke University. She received training in Internal Medicine, Gastroenterology and Hepatology at the Mayo Clinic, Rochester, MN and obtained a MPH degree with emphasis in epidemiology, public health and clinical investigation at the University of Florida, Gainesville, Florida. Since first reporting on nonalcoholic steatohepatitis (NASH) as a cause of cryptogenic cirrhosis nearly 25 years ago, her clinical and research area of interest have been in the field of NAFLD, associated risk factors for disease acquisition and progression and the discovery of novel approaches to treatment. She has expertise in the design and conduct of clinical trials in NAFLD/ NASH including investigator-initiated, industry sponsored and NIH-funded clinical studies evaluating new therapies and biomarkers for NAFLD and NASH. She collaborates extensively with multidisciplinary teams to translate new compounds to first-in-man clinical studies and conduct clinic-to-bench and bench-to-clinic research to define pathogenic mechanisms underlying NAFLD acquisition and progression. She is a key opinion leader in the field of NASH therapeutics, a member of the Liver Forum, and advisor/ consultant to many drug-development and biomarker development companies and FDA in the area of diagnostics and therapeutics for NASH. Her experience extend from site investigator, to medical monitor and coordinating principal investigator for global NASH studies. Dr. Abdelmalek is a Fellow of American College of Physicians, American College of Gastroenterology and American Association for the Study of Liver Disease. She has been a standing member of the NIH sponsored NASH CRN for the past 15 years and has authored over 200 publications in the field of liver disease, the majority of which are in the area of NAFLD/NASH.

Roger M. Perlmutter, M.D., Ph.D.

Executive vice president and president

Merck Research Laboratories

Before joining Merck, Roger was executive vice president and head of R&D at Amgen from January 2001 to February 2012. Previously, Roger worked at Merck Research Laboratories and held roles of increasing responsibility from 1997 to 2001, including executive vice president of worldwide basic research and preclinical development. More recently, he served as a director of several biotechnology companies and was a science partner at the Column Group, a biotechnology-focused venture capital firm. Roger was previously a professor in the departments of immunology, biochemistry and medicine at the University of Washington, Seattle, and served as chairman of its department of immunology, where he was a Howard Hughes Medical Institute investigator. He was also a lecturer in the Division of Biology at the California Institute of Technology, Pasadena. Roger received his M.D. and Ph.D. from Washington University in St. Louis and his B.A. from Reed College. He pursued clinical training in internal medicine at Massachusetts General Hospital, Boston, and at the University of California, San Francisco. Roger is a fellow of the American Academy of Arts and Sciences and the American Association for the Advancement of Science.

Dean Y. Li, M.D., Ph.D.


Merck Research Laboratories

Dean Y. Li, M.D., Ph.D. joined Merck in 2017 as Vice President and head of Translational Medicine. Prior to joining Merck, Dr. Li held positions of increasing responsibility in translational medical research at the University of Utah. Most recently he served as the H.A. & Edna Benning Professor of Medicine and Cardiology, Chief Scientific Officer, Associate Vice President and Vice Dean at the University of Utah Health System. During his tenure at the University of Utah, he co-founded multiple biotech companies based upon research conducted in his laboratory, including Recursion Pharmaceuticals, Hydra Biosciences and Navigen Pharmaceuticals. Dean received a bachelor’s degree from the University of Chicago and his medical degree, doctorate degree, and training in clinical medicine and cardiology at Washington University School of Medicine in St. Louis. He is a member of the American Society for Clinical Investigation and the Association of American Physicians.

Bill Rieflin

Chief Executive Officer and Director

NGM, Moderator

Mr. Rieflin brings over 20 years of industry experience to NGM. Most recently, he was President of XenoPort, Inc. (Nasdaq: XNPT) and currently serves on XenoPort’s Board of Directors. Prior to that, he was Executive Vice President, Administration, Chief Financial Officer, General Counsel and Secretary for Tularik, Inc. (Nasdaq: TLRK), which was acquired by Amgen, Inc. in 2004. Previously, he was Vice President, Human Resources, General Counsel and Secretary for AMSCO International, Inc. (NYSE: ASZ). He was also an associate at Sidley & Austin in the corporate and securities department. He began his career as a sales representative for American Hospital Supply Corporation. Mr. Rieflin earned his B.S. from Cornell University, his M.B.A. from the University of Chicago Booth School of Business and his J.D. from Stanford Law School.

Siobhan Nolan Mangini

Chief Financial Officer


Prior to joining NGM, Ms. Nolan Mangini served as President and Chief Financial Officer (CFO) of Castlight Health, a publicly traded San Francisco-based healthcare technology company. She joined Castlight in 2012 and assumed roles of increasing responsibility, ultimately being appointed CFO in 2016 followed by her additional appointment as President in 2019. At Castlight, Ms. Nolan Mangini was responsible for a wide range of functions including strategic and corporate planning, finance, investor relations, people, legal, real estate, customer support and business operations. Prior to joining Castlight, Ms. Nolan Mangini worked as a management consultant at Bain & Company, specializing in the health care and private equity practices. She began her career at the Henry J. Kaiser Family Foundation as a financial associate responsible for managing the allocation of the foundation’s endowment. Ms. Nolan Mangini currently serves on the Board of Directors of Artemis Health. Ms. Nolan Mangini has a Master of Business Administration from the Graduate School of Business at Stanford University, a Master of Public Administration from the Kennedy School of Government at Harvard University and a Bachelor of Science in Economics from the Wharton School at the University of Pennsylvania.

Alex Schwartz

Executive Director, Investor Relations


Mr. Schwartz serves as NGM Bio’s Head of Investor Relations. Before joining NGM Bio in 2020, Mr. Schwartz was Head of Investor Relation at Esperion Therapeutics where led communications through four drug approvals and commercial launches, pivotal Phase 3 data readouts, European & Japanese partnerships as well as Investor Days. Prior to Esperion Therapeutics, Alex was a Senior Equity Research Analyst at Stifel Nicolaus & Company, an investment bank, where he published stock research on promising oncology, autoimmune disease, neurology, and metabolic companies. Alex completed his MBA in Finance from Boston College and his BS in Finance from Indiana University.
First Name
Last Name
Email Address